New immunotherapy ’highly effective’ against hepatitis B virus

Transmission electron microscopic image revealed the presence of HBV particles - Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world. Each year, globally, chronic HBV causes an estimated 880,000 deaths from liver cirrhosis and hepatocellular carcinoma/liver cancer (HCC). The pioneering study used immune cells isolated directly from patient liver and tumour tissue ,  to show that targeting acyl-CoA:cholesterol acyltransferase (ACAT), an enzyme that helps to manage cholesterol levels in cells*, was highly effective at boosting immune responses. Published in  Nature Communications , the findings show that blocking the activity of ACAT with ACAT inhibitors boosts the specific immune cells that can fight both the virus and associated cancerous tumours, demonstrating its effectiveness as an immunotherapy. Inhibiting ACAT was also found to impede HBV's own replication, thereby also acting as a direct antiviral. ACAT inhibitors such as avasimibe, taken orally, have previously been shown to be well-tolerated as cholesterol-lowering drugs in humans. Explaining the study, lead author Professor Mala Maini (UCL Division of Infection & Immunity), said: "Chronic hepatitis B virus infection is a major global health problem and the most common cause of liver cancer in the world.